Location Directory

Clinical trials in Phoenix, Arizona

This page shows live ClinicalTrials.gov search results for Phoenix, Arizona, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 10:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

8145

Shown on this page

Current sort

Institutions in Phoenix

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Mayo Clinic

Live official records

Open in full search

Conditions: Multiple Myeloma, Recurrent Multiple Myeloma, Refractory Multiple Myeloma, Smoldering Multiple Myeloma
Interventions: Bone Marrow Biopsy, Dexamethasone, Lenalidomide, Pomalidomide; Procedure · Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 4
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Jacksonville, Florida + 1 more

Conditions: Generalized Myasthenia Gravis
Interventions: Remibrutinib (Blinded), Placebo, Remibrutinib (Open Label); Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2033
U.S. locations: 23
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Fullerton, California + 18 more

Conditions: SARS-CoV-2
Interventions: mRNA-1273, mRNA-1283, Placebo; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 50 Years to 64 Years
Enrollment: 30,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 150
States / cities: Birmingham, Alabama • Cullman, Alabama • Mobile, Alabama + 127 more

Conditions: Gout, Arthritis, Gouty, Hyperuricemia, Gout Chronic
Interventions: AR882 50 mg, AR882 75 mg, Placebo; Drug
Lead sponsor: Arthrosi Therapeutics; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 866 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 83
States / cities: Birmingham, Alabama • Huntsville, Alabama • Peoria, Arizona + 74 more

Conditions: Neovascular Age-Related Macular Degeneration
Interventions: PDS Implant with Ranibizumab 100 mg/mL; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 50 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2029
U.S. locations: 81
States / cities: Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 69 more

Conditions: Multiple Sclerosis
Interventions: SAR441344 IV, placebo IV, SAR441344 SC, placebo SC, MRI contrast-enhancing preparations; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 4
States / cities: Phoenix, Arizona • Tampa, Florida • Charlotte, North Carolina + 1 more

Conditions: Multiple Myeloma
Interventions: Cilta-cel, Pomalidomide, Bortezomib, Dexamethasone, Daratumumab; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 419 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 19
States / cities: Birmingham, Alabama • Phoenix, Arizona • Stanford, California + 16 more

Conditions: CDK Gene Mutation, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm, NTRK Family Gene Mutation, PI3K Gene Mutation, ROS1 Gene Mutation, KRAS G12C Mutation
Interventions: Abemaciclib, PI3K Inhibitor paxalisib, Entrectinib, Adagrasib; Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 435
States / cities: Anchorage, Alaska • Phoenix, Arizona • Scottsdale, Arizona + 306 more

Conditions: Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC)
Interventions: REGN15505, REGN15505+Cemiplimab, REGN15505+REGN4336; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 265 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 6
States / cities: Goodyear, Arizona • Duarte, California • Tampa, Florida + 3 more

Conditions: Respiratory Syncytial Virus Infections
Interventions: RSVPreF3 OA investigational vaccine; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 60 Years and older
Enrollment: 1,720 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 18
States / cities: Mobile, Alabama • Phoenix, Arizona • Riverside, California + 15 more

Conditions: Irritability Associated With Autism Spectrum Disorder
Interventions: KarXT, KarX-EC, KarXT + KarX-EC Matching Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 5 Years to 17 Years
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 23
States / cities: Phoenix, Arizona • Glendale, California • Los Angeles, California + 19 more

Conditions: Plaque Psoriasis
Interventions: JNJ-77242113, JNJ-77242113 Matching Placebo, Deucravacitinib, Deucravacitinib Matching Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 731 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 37
States / cities: Phoenix, Arizona • Encinitas, California • Encino, California + 32 more

Clinical trials in Phoenix, Arizona

Filter and sort this location

Institutions in Phoenix

Live official records

Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma

A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis

A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19)

Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-301)

Extension Study for the Port Delivery System With Ranibizumab (Portal)

Proof-of-concept Study for SAR441344 (Frexalimab) in Relapsing Multiple Sclerosis

A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma

Genetic Testing in Guiding Treatment for Patients With Brain Metastases

REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma

Immunogenicity, Safety, Reactogenicity and Persistence of an Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above

A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism Spectrum Disorder

A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)